Cipla to make drugs in Iran in deal with Ahran Tejarat

By Gareth Macdonald

- Last updated on GMT


Related tags Drug Pharmaceutical drug

Cipla Ltd has formed a joint venture with Ahran Tejarat Company to manufacture and sell drugs in Iran.

The agreement – announced on the Bombay Stock Exchange (BSE) – will see Cipla’s Netherlands-based subsidiary take a 75% stake in the Iran-based JV for €16.8m ($17.5m).

Under the deal, Issat Company, which is owned by Ahran Tejarat, will become the joint venture entity. The firm holds an Iranian manufacturing license, but does not currently produce medicines or generate revenue.

Cipla has been interested in the Iranian pharmaceutical since at least 2014.

In October of that year, the India headquartered drug firm announced​ its intention to set up a manufacturing plant in Iran in collaboration with a distributor in the country.


Pharmaceuticals and medical equipment are not restricted under international sanctions imposed on Iran after the 1979 revolution. Despite this, drug production in the country is limited with few international manufacturers involved. 

A 2013​ report by the Woodrow Wilson International Center for Scholars suggested that, despite humanitarian provisions included in the sanctions, some pharmaceutical products are in short supply.

The authors wrote that: "Sanctions are affecting the supply of the most advanced medicines, providing relief in the most dire cases of illness, including cancer, multiple sclerosis, and hemophilia​."

Related news

Related products

show more

Increasing the Bioavailability of Oncology Drugs

Increasing the Bioavailability of Oncology Drugs

Content provided by Lonza Small Molecules | 13-Nov-2023 | White Paper

Oral tyrosine kinase inhibitors (TKIs) are a class of cancer drugs that can be highly susceptible to issues with solubility in the gastrointestinal tract

Efficient Freezing & Storage of Biopharmaceuticals

Efficient Freezing & Storage of Biopharmaceuticals

Content provided by Single Use Support | 06-Nov-2023 | White Paper

Various options exist for freezing biopharmaceutical bulk material, but selecting the most effective and efficient approach for each cold chain can be...

Manufacturing Drugs with Highly Potent APIs

Manufacturing Drugs with Highly Potent APIs

Content provided by Altasciences | 28-Sep-2023 | White Paper

In this issue of The Altascientist, we examine the critical considerations for the safe and compliant manufacture of drugs with highly potent APIs (HPAPIs),...

Follow us


View more